Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. Home/
    2. Media Center
    A female scientist wearing full PPE working in a lab setting

    Media Center

    Explore the latest Johnson & Johnson news, press materials and downloadable media assets—everything you need to inform your storytelling.
    A male surgeon in full PPE using a J&J medical device during a surgery in the OR

    Multimedia for storytelling

    Our refreshed Media Center library allows you to search for media assets across a variety of categories.
    View library

    Press releases

    Press Releases

    Sorry, I don't understand. Please try again

    Date
    Topic
    There are 2,371 results that match your search.
    • Innovative Medicine
      November 10, 2026

      Johnson & Johnson showcases continued hematology leadership and next-generation innovation at ASH 2026

      · New TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs) Phase 3 data demonstrate reduced risk of disease progression in relapsed or refractory multiple myeloma as early as second line · First results from ramantamig, an investigational trispecific antibody, with DARZALEX® (daratumumab) and lenalidomide in transplant-eligible newly diagnosed multiple myeloma showed deep and durable responses across multiple lines of therapy · Positive Phase 2 results for bleximenib in relapsed or refractory acute myeloid leukemia with KMT2A rearrangements or NPM1 mutations, supported by two Breakthrough Therapy Designations · First data for a novel, potentially disease-modifying CALRmut × CD3 T-cell engaging antibody targeting a disease-defining driver mutation in essential thrombocythemia, supported by Breakthrough Therapy and Priority Medicines designations
      Read more
    • November 10, 2026

      Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study

      · CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies · Two positive Phase 3 studies will support a planned U.S. FDA submission of CAPLYTA for bipolar mania, reinforcing its potential to address both depressive and manic episodes of bipolar disorder
      Read more
    • Innovative Medicine
      November 9, 2026

      Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

      · First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer · Deep and sustained PSA responses observed with every-six-week dosing, with 73% (11 of 15 patients) achieving reductions of at least 50% and nearly half achieving reductions of at least 90% in Phase 1 study · With an encouraging safety profile, findings show potential for outpatient dosing as the combination advances to Phase 3
      Read more

    Contact Global Media Relations

    Contact us
    WHQ Exterior New Brunswick Johnson Hall

    Discover J&J